Emerg Infect Dis. 2022 Jun;28(6):1110-1116. doi: 10.3201/eid2806.220131.
Annually, Shigella spp. cause ≈188 million cases of diarrheal disease globally, including 500,000 cases in the United States; rates of antimicrobial resistance are increasing. To determine antimicrobial resistance and risk factors in San Diego, California, USA, we retrospectively reviewed cases of diarrheal disease caused by Shigella flexneri and S. sonnei diagnosed during 2017-2020. Of 128 evaluable cases, S. flexneri was slightly more common than S. sonnei; most cases were in persons who were gay or bisexual cisgender men, were living with HIV, were unhoused, or used methamphetamines. Overall, rates of resistance to azithromycin, fluoroquinolones, ampicillin, and trimethoprim/sulfamethoxazole (TMP/SMX) were comparable to the most recent national data reported from the Centers for Disease Control and Prevention; 55% of isolates were resistant to azithromycin, 23% to fluoroquinolones, 70% to ampicillin, and 83% to TMP/SMX. The rates that we found for TMP/SMX were slightly higher than those in national data.
每年,志贺氏菌属会导致全球约 1.88 亿例腹泻病,包括美国的 50 万例;抗菌药物耐药率正在上升。为了确定美国加利福尼亚州圣地亚哥的抗菌药物耐药情况和危险因素,我们回顾性分析了 2017 年至 2020 年期间诊断的由福氏志贺菌和宋内志贺菌引起的腹泻病病例。在 128 例可评估的病例中,福氏志贺菌略多于宋内志贺菌;大多数病例发生在同性恋或双性恋顺性别男性中,他们与艾滋病毒感染者同住,无家可归或使用冰毒。总体而言,对阿奇霉素、氟喹诺酮类、氨苄西林和复方磺胺甲噁唑(TMP/SMX)的耐药率与疾病控制与预防中心报告的最新全国数据相当;55%的分离株对阿奇霉素耐药,23%对氟喹诺酮类耐药,70%对氨苄西林耐药,83%对 TMP/SMX 耐药。我们发现的 TMP/SMX 耐药率略高于全国数据。